Eurofins Scientific has signed a definitive agreement to acquire Boston Heart Diagnostics Corporation for an initial value of $140 million, subject to post-closing adjustments, plus an earn-out payment to the sellers that is expected to be in excess of $60 million upon achievement of certain milestones. Read the full story

Recent market research analysis by Current Agreements shows that partnering in the last decade has seen an increase in cardiovascular deals with an increase in modern diagnostic technology development. Read the full story

Isis Pharmaceuticals, a leader in antisense drug discovery, has emerged as a top 50 big biotech company with its business strategy. Read the full story

Pharma news: University of Colorado faculty researchers attracted $861.04 million in research awards in the 2013-14 fiscal year, based on preliminary figures. Read the full story

Actelion is a Switzerland based biopharmaceutical company discovering, developing and commercializing products for unmet medical needs. Read the full story

Actelion has announced only 1 M&A deal since 2009, with the deal being the acquisition of Ceptaris Therapeutics. Read the full story

Actelion, a big biotech company based in Switzerland, has a fully integrated business model focused on innovative treatments to serve high unmet medical needs. Read the full story

Medical device marker, HeartWare International acquires CircuLite for $350 million. Read the full story

Lorem Vascular and Cytori Therapeutics have joined together for a pharma licensing deal to commercialize Cytori Cell Therapy in China.

Read the full story

XENTION and SERVIER pharma partners by entering into a multi-year agreement for the development and commercialisation of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of atrial fibrillation Read the full story